NewsBenzingaBTIG ribadisce il giudizio Buy su Caris Life Sciences, mantiene il target di prezzo di 38 dollari BTIG ribadisce il giudizio Buy su Caris Life Sciences, mantiene il target di prezzo di 38 dollari Benzinga 2026.11.05 11:06 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3